Page 1

FOR IMMEDIATE RELEASE Exhibit 99.1 Therapeutics MD TherapeuticsMD Announces Second Quarter 2021 Financial Results 2Q21 total net product revenue increased by 17 % over 1Q21 to $ 23 million - -ANNOVERAⓇ prescription growth supported by improved access to providers and increased telemedicine options for patients - - Prescriptions for IMVEXXY® grew by 8 % over 1Q21 , outpacing the VVA market - -Centers for Medicare and Medicaid Services recommended that ANNOVERA receive its own unique national J - Code that could be live as early as Q421- - vitaCare signed new customer and pipeline continues to grow - - Conference call scheduled for 8:30 a.m. ET today - BOCA RATON , Fla . – August 4 , 2021 - TherapeuticsMD , Inc. ( " TXMD " or the " Company " ) ( NASDAQ : TXMD ) , an innovative , leading women's healthcare company , today reported financial results for the second quarter ended June 30 , 2021 . " We continue to make steady progress in line with our expectations related to ANNOVERA and IMVEXXY driving prescription growth , net margins and broader patient access . Importantly , we are seeing improved access to health care providers for our sales force and expansion of our relationships in the telemedicine channel and believe we are well positioned to grow our products across all channels . Our overall volumes and net revenues were very healthy , and vitaCare prescription services is building the foundation for growth in the future . vitaCare recently signed its third customer contract and has a strong pipeline of more than 30 potential customers . In addition , we continue to evaluate investment into vitaCare , including potentially selling a minority stake , which could provide a non - dilutive source of capital for TXMD shareholders , " said Robert G. Finizio , Chief Executive Officer of TherapeuticsMD . Second Quarter 2021 Financial Results and Business Highlights Net Product Revenue ANNOVERA IMVEXXY BIJUVA Prescription vitamin Product revenue , net License revenue Total revenue , net ANNOVERA ( segesterone acetate and ethinyl estradiol vaginal system ) Three Months Ended June 30 , March 31 , 2021 2020 2021 $ 9,555 $ 1,835 $ 8,750 9,838 5,086 7,012 2,156 1,352 2,445 1,452 2,428 1,425 23,001 10,701 19,632 234 $ 23,001 $ 10,701 $ 19,866 ANNOVERA net product revenue of $ 9.6 million for the second quarter of 2021 increased by $ 7.7 million compared to $ 1.8 million for the second quarter of 2020 and $ 0.8 million compared to $ 8.8 million for the first quarter of 2021 . Net revenue per unit , calculated from sales to wholesalers and pharmacies , was $ 1,157 for the second quarter of 2021 . Approximately 7,299 ANNOVERA prescriptions were dispensed to patients during the second quarter of 2021. Prescriptions increased 202 % compared to the second quarter of 2020 and 17 % compared to the first quarter of 2021. Refill rates remained strong at approximately 50 % for eligible patients . IMVEXXY ( estradiol vaginal inserts ) IMVEXXY net product revenue of $ 9.8 million for the second quarter of 2021 increased by $ 4.8 million compared to $ 5.1 million for the second quarter of 2020 and $ 2.8 million compared to $ 7.0 million for the first quarter of 2021 . Net revenue per unit , calculated from sales to wholesalers and pharmacies , was $ 64 for the second quarter of 2021 , reflecting a 56 % improvement in net price compared to the second quarter of 2020. This is the fourth consecutive quarter that IMVEXXY has achieved a record net revenue per unit .